Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Carl Zeiss Meditec AG, DE0005313704

Carl Zeiss Meditec AG, DE0005313704

08.02.2021 - 07:04:19

Successful start to FY 2020/21 for Carl Zeiss Meditec

region returns to growth - EMEA[2] and Americas almost stable

Revenue in in the EMEA region decreased slightly by -1.8% (adjusted for currency effects: +0.1%), to ?108.7m (prior year: ?110.7m). The trend in the markets of Germany, France and Southern Europe was stable.

The Americas region recorded a mainly currency-related decline in revenue of -6.4% (adjusted for currency effects: -0.2%) to ?102.0m (prior year: ?109.0m). On a currency-adjusted basis, the USA almost matched the prior year's level.

Revenue in the APAC region increased again for the first time since the start of the crisis, amounting to ?158.2m compared with ?150.0m in the same period of the prior year (+5.5%; adjusted for currency effects: +6.6%). Once again, the strongest contributions to growth were generated in China and South Korea. There was only a slight decline in revenue in Japan.

Operating result increased significantly year-on-year

The operating result (earnings before interest and taxes: EBIT) increased to ?73.4m in the first three months of fiscal year 2020/21 (prior year: ?56.8m). Low selling and marketing expenses, in particular, contributed to this. EBIT also includes positive one-time income of ?2.4m from the sale of a property. The EBIT margin increased to 19.9% (prior year: 15.4%). Adjusted for special effects, this resulted in an increase to 19.8% (prior year: 15.8%). Earnings per share rose to ?0.52 (prior year: ?0.43).

Carl Zeiss Meditec expects revenue and EBIT to continue to recover over the further course of fiscal year 2020/21 compared with the prior year, which had been dominated by the COVID-19 pandemic.

Revenue by strategic business unit

All figures in ?m 3 months 2020/21 3 months 2019/20 Change from prior year Change from prior year (currency-adjusted) Ophthalmic Devices 283.4 269.4 +5.2% +8.2% Microsurgery 85.5 100.3 -14.7% -12.3% Consolidated 368.9 369.7 -0.2% +2.6% ?

Revenue by region

All figures in ?m 3 months 2020/21 3 months 2019/20 Change from prior year Change from prior year (currency-adjusted) EMEA 108.7 110.7 -1.8% +0.1% Americas 102.0 109.0 -6.4% -0.2% APAC 158.2 150.0 +5.5% +6.6% Consolidated 368.9 369.7 -0.2% +2.6% ?

Further information on our publication and the Analyst Conference Call on the results for the first three months of fiscal year 2020/21 can be found at?https://www.zeiss.com/meditec-ag/investor-relations/reports-publications.html


Contact for investors and press

Sebastian Frericks Director Investor Relations, Carl Zeiss Meditec AG Phone: +49 (0)3641 220-116 Email: investors.meditec@zeiss.comwww.zeiss.de/presse[1] Asia/Pacific[2] Europe, Middle East, Africa

08.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Carl Zeiss Meditec AG G?schwitzer Str. 51-52 07745 Jena, Germany

Germany Phone: +49 (0)3641 220-0 Fax: +49 (0)3641 220-112 E-mail: investors.meditec@zeiss.com Internet: www.zeiss.de/meditec-ag/ir ISIN: DE0005313704 WKN: 531370 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1166466 ? End of News DGAP News Service


@ dgap.de